I listened to most of the call, not all, but my sense was they were stressing their remaining pipeline.  Oh and by the way, the stopped the last existing pain trial so one less pipeline item.  

 

I think the stock is trading at its value with the assumption that the Trofinetide will be approved.  I see the potential for the stock to hit $30 with approval of Trofinetide considering Acadia would then be profitable.

 

The only other significant pipeline item is the negative symptoms of Schizophrenia.  I have high hopes for this indication.  Having said that, assuming positive results come out in 2023 and assuming 1 year till approval (2024), I would think we only have a few years left of patent.

 

They also mentioned other early stage drugs, but they are so far off I wouldn't put much value in them.  Just my 2 cents.